Home > Insider Trading > Filing (0001144204-15-023553)

Filing Details

Accession Number:: 0001144204-15-023553
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2015-04-17 16:13:58
Reporting Period:: 2015-04-15

Filing Date:: 2015-04-17
Accepted Time:: 2015-04-17 16:13:58
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1410098	Cormedix Inc.	CRMD	Pharmaceutical Preparations (2834)	000000000

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1360968	Randy Milby	C/O Cormedix Inc. 745 Route 202-206, Suite 303 Bridgewater NJ US 08807	Chief Executive Officer	Yes	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock, $0.001 Par Value Per Share	Acquisiton	2015-04-15	730	$8.55	52,166	No	4	P	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Direct

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock, $0.001 Par Value Per Share	196,243	Indirect	MW Bridges LLC

Reported Derivative Holdings

Show Other Fields >>

Sec. Name	Sec. Type	Price	Date	Expiration Date	Amount	Remaning Holdings	Nature of Ownership
Common Stock, $0.001 Par Value Per Share	Stock Option (right to buy)	$2.02		2024-01-09	100,000	100,000	Direct
Common Stock, $0.001 Par Value Per Share	Series C-3 Non-Voting Convertible Preferred Stock	$1.00			237,000	23,700	Direct
Common Stock, $0.001 Par Value Per Share	Warrant (right to purchase Common Stock)	$1.25	2015-01-08	2020-01-08	118,500	118,500	Direct
Common Stock, $0.001 Par Value Per Share	Series C-3 Non-Voting Convertible Preferred Stock	$1.00			13,000	1,300	Indirect
Common Stock, $0.001 Par Value Per Share	Warrant (right to purchase Common Stock)	$1.25	2015-01-08	2020-01-08	6,500	6,500	Indirect
Common Stock, $0.001 Par Value Per Share	Stock Option (right to buy)	$0.90		2023-03-20	437,500	437,500	Direct
Common Stock, $0.001 Par Value Per Share	Stock Option (right to buy)	$0.68		2022-12-05	100,000	100,000	Direct
Common Stock, $0.001 Par Value Per Share	Stock Option (right to buy)	$0.29		2022-05-14	50,000	50,000	Indirect
Common Stock, $0.001 Par Value Per Share	Warrant (right to purchase Common Stock)	$0.40	2012-09-20	2017-09-20	62,500	62,500	Indirect
Common Stock, $0.001 Par Value Per Share	Stock Option (right to buy)	$5.00		2025-02-24	75,000	75,000	Direct

Expiration Date	Amount	Remaning Holdings	Nature of Ownership
2024-01-09	100,000	100,000	Direct
	237,000	23,700	Direct
2020-01-08	118,500	118,500	Direct
	13,000	1,300	Indirect
2020-01-08	6,500	6,500	Indirect
2023-03-20	437,500	437,500	Direct
2022-12-05	100,000	100,000	Direct
2022-05-14	50,000	50,000	Indirect
2017-09-20	62,500	62,500	Indirect
2025-02-24	75,000	75,000	Direct

Footnotes

This purchase of newly issued shares was pursuant to an automatic payroll deduction arrangement with the reporting person.
The reporting person beneficially owns these securities through his ownership interest in MW Bridges LLC (an entity through which he has voting and investment control).
The option vested 100% on January 10, 2014.
On January 8, 2014, the reporting person acquired in a private placement (i) 23,700 shares of the Company's Series C-3 Non-Voting Convertible Prefered Stock, each share is convertible into 10 shares of the Common Stock, $0.001 par value per share at a conversion price of $1.00 per share; and (ii) a five-year warrant to purchase Common Stock at an exercise price of $1.25 per share. The Series C-3 Preferred Stock and the warrants were purchased together at a purchase price of $10.00 per share for each share of Series C-3 Preferred Stock.
On January 8, 2014, the reporting person, through his ownership in MW Bridges LLC (an entity through which he has voting and investment control), acquired in a private placement (i) 1,300 shares of the Company's Series C-3 Non-Voting Convertible Preferred Stock, each share is convertible into 10 shares of the Common Stock, $0.001 par value per share at a conversion price of $1.00 per share; and (ii) a five-year warrant to purchase Common Stock at an exercise price of $1.25 per share. The Series C-3 Preferred Stock and the warrants were purchased together at a purchase price of $10.00 per share for each share of Series C-3 Preferred Stock.
The original grant of 500,000 options were to vest based on performance milestones running through December 31, 2014, pursuant to which 62,500 were forfeited for failure to meet all of the vesting requirements
These options vested as follows: (a) fifty percent (50%) on the date of issuance of the CE Mark certification for Neutrolin in Europe, which occurred on July 5, 2013, and (b) fifty percent (50%) on December 31, 2013.
These options vested 100% upon receipt of CE Mark approval for the Company's Neutrolin product candidate on July 5, 2013.
These options were granted on February 24, 2015, and vested immediately.